The Biotechnology Industry is witnessing an increase in collaborative partnerships with a view to developing newer techniques. During its “green wave” period the industry produced a number of agricultural applications. During its “red wave”, there were a number of developments in the medical space to target disease prevention and management. In its “white wave”, industrial applications were at the forefront. A further rise in demand for therapeutics and diagnostic solutions on principles of ‘red wave’, DNA sequencing, and recombinant technology is expected to propel huge growth. Prevention, management and cure of chronic diseases such as hepatitis B, cancer, HIV and childhood disorders is expected to further fuel growth. Optimized development of DNA technology is expected to serve this sector as a high impact rendering growth driver. It is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. Personalised medicine, biosimilars, bioinformatics, management of genomic data through studies on plants, animals and human genomes is also expected to drive segment growth during the forecast period.

Our reports provide application insights, technology insights, regional insights and competitive insights on biomaterials, genomics, proteomics, bioinformatics, biomarkers, biosimilars, drug delivery and discovery, stem cell, food and agriculture technology and tissue regeneration technology. To know more about our offerings in the Biotechnology sector, contact us.

Biotechnology Market Research Reports

The Biotechnology Industry is witnessing an increase in collaborative partnerships with the primary view of developing newer and pathbreaking technology. The market is set to expand at 9.9 percent CAGR to hit USD 775 billion by 2024 mainly on account of increase in the incidence of chronic diseases such as diabetes and cancer, development of technology innovation and favorable government conditions. The ratio of chronic disease all around the globe is continuously increasing, which is analyzed to propel growth in the industry overall. According to recent data, the estimated number of people affected by the chronic disease will rise to 629 million by 2045. Approximately half of America’s population suffers from at least one chronic disease and this number is growing continuously. These statistics are expected to pave the way for opportunities in the biotechnology market.

The industry has experienced what is known as a ‘wave’ phenomenon. During its ‘green wave’ period the industry produced a number of agricultural applications. During its ‘red wave’, there were a number of developments in the medical space to target disease prevention and management. In its ‘white wave’, industrial applications were at the forefront. A further rise in demand for therapeutic and diagnostic solutions on principles of ‘red wave’, DNA sequencing, and recombinant technology is expected to propel huge growth. Prevention, management and cure of chronic diseases such as hepatitis B, cancer, HIV and childhood disorders is also expected to boost fuel growth. Optimized development of DNA technology is expected to serve this sector as a high impact-rendering growth driver. It is expected to encourage researchers and manufacturers to increase research and development initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. Personalized medicine, biosimilars, bioinformatics, management of genomic data through studies on plants, animals and human genomes is also expected to drive segment growth during the forecast period.

Global Market Studies’ Biotechnology Market Research reports provide application insights, technology insights, regional insights and competitive insights vis-a-vis the subsectors of biomaterials, biomanufacturing, genomics, proteomics, bioinformatics, biomarkers, biosimilars, drug delivery and discovery, stem cell, food and agriculture technology and tissue regeneration technology, among others. Key competitor analysis includes that of Agilent Technologies, Amgen, Abbott Laboratories, Bio-Rad Laboratories, BioGen Medical Instruments, Danaher, Merck, F. Hoffmann-La Roche, Illumina, PerkinElmer, Thermo Fisher Scientific and Qiagen.

Contact us at Global Market Studies to know more about our offerings in the Biotechnology sector.